Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2018048234) DEGLYCOSYLATED ANTIBODY SPECIFICALLY BINDING TO CLEC14A AND USES THEREOF
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2018/048234 International Application No.: PCT/KR2017/009851
Publication Date: 15.03.2018 International Filing Date: 08.09.2017
IPC:
C07K 16/18 (2006.01) ,A61K 39/395 (2006.01) ,A61K 39/00 (2006.01)
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
16
Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18
against material from animals or humans
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39
Medicinal preparations containing antigens or antibodies
395
Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39
Medicinal preparations containing antigens or antibodies
Applicants:
주식회사 우리기술 WOORI TECHNOLOGIES CORPORATION [KR/KR]; 서울시 마포구 월드컵북로56길 9 우리기술빌딩4층 4F., Woori Technologies Bldg. 9, World Cup buk-ro 56-gil, Mapo-gu, Seoul 03923, KR
Inventors:
이석묵 LEE, Sukmook; KR
김택근 KIM, Taek-Keun; KR
김미라 KIM, Mi Ra; KR
장지혜 JANG, Ji Hye; KR
Agent:
이처영 LEE, Cheo Young; KR
장제환 CHANG, Je Hwan; KR
Priority Data:
10-2016-011557708.09.2016KR
Title (EN) DEGLYCOSYLATED ANTIBODY SPECIFICALLY BINDING TO CLEC14A AND USES THEREOF
(FR) ANTICORPS DÉGLYCOSYLÉ SE LIANT SPÉCIFIQUEMENT À CLEC14A ET SES UTILISATIONS
(KO) clec14a에 특이적으로 결합하는 탈당화 항체 및 그 용도
Abstract:
(EN) The present invention relates to a deglycosylated antibody which specifically binds to C-type lectin domain family 14, member A (clec14a), and uses thereof. More specifically, the present invention relates to a deglycosylated antibody which comprises a light chain variable region including CDR1 of a particular sequence and specifically binds to clec14, and uses thereof, such as a pharmaceutical composition for the prevention or treatment of angiogenesis-related diseases comprising the antibody.
(FR) La présente invention concerne un anticorps déglycosylé qui se lie spécifiquement à la famille 14 du domaine de la lectine de type C, élément A (clec14a) et ses utilisations. Plus spécifiquement, la présente invention concerne un anticorps déglycosylé qui comprend une région variable de chaîne légère comprenant une région CDR1 d'une séquence particulière et se lie spécifiquement à clec14, et leurs utilisations, telles qu'une composition pharmaceutique pour la prévention ou le traitement de maladies associées à l'angiogenèse comprenant l'anticorps.
(KO) 본 발명은 C-타입 렉틴 도메인 패밀리 14, 멤버 A(clec14a)에 특이적으로 결합하는 탈당화 항체 및 그 용도에 관한 것이다. 더욱 상세하게, 본 발명은 특정 서열의 CDR1을 포함하는 경쇄 가변영역을 포함하고, clec14에 특이적으로 결합하는 탈당화 항체 및 이의 용도 예를 들어, 상기 항체를 포함하는 혈관신생 관련 질환 예방 또는 치료용 약학적 조성물에 관한 것이다.
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: Korean (KO)
Filing Language: Korean (KO)